Harrow, Inc. Common Stock
$33.08
-$0.05 (-0.15%)
$31.90Day Range$33.34
Key Statistics
Market Cap
$1.24B
Shares Outstanding
37.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 30, 2007
Round Lot
100
Locale
US
Trading Data
Day Open
$32.93
Day High
$33.34
Day Low
$31.90
Volume
1.74M
VWAP
$32.54
Prev Close
$33.13
Transactions
--
Acc. Volume
--
About Harrow, Inc. Common Stock
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
PHARMACEUTICAL PREPARATIONSSIC 2834373 employees1A BURTON HILLS BLVD, NASHVILLE, TN615.733.4731IPO Apr 30, 2007US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001360214
- Composite FIGI
- BBG000QXWY44
- Share Class FIGI
- BBG001SSTRN9
- Ticker Root
- HROW
- SIC Code
- 2834
About Harrow, Inc. Common Stock (HROW) Stock
Harrow, Inc. Common Stock (HROW) closed the 2026-09-18 session at $33.08, down 0.15% versus the previous close (-0.05). The stock opened at $32.93 and traded between $31.90 and $33.34 during that session. Session trading volume was 1.7M shares. The volume-weighted average price (VWAP) is $32.54.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
Harrow, Inc. Common Stock has a market capitalization of $1.24 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. HROW is listed on the XNAS exchange. The company employs approximately 373 people. Harrow, Inc. Common Stock is headquartered in NASHVILLE, TN. The recorded listing date is 2007-04-30.
On this page you can find market HROW stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.